EMA/PE/0000243095
Submitted by Anonymous (not verified) on 9 March 2026 - 10:39
EMA/PE/0000243095
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232930
Submitted by Anonymous (not verified) on 9 March 2026 - 10:35
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232930
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232848
Submitted by Anonymous (not verified) on 9 March 2026 - 10:34
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232848
National Innovation Offices Contacts
Submitted by Anonymous (not verified) on 9 March 2026 - 10:11
National Innovation Offices Contacts
Organisation Management Service (OMS)
Submitted by Anonymous (not verified) on 9 March 2026 - 8:29
Organisation Management Service (OMS)
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000221604
Submitted by Anonymous (not verified) on 6 March 2026 - 15:06
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000221604
Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000225594
Submitted by Anonymous (not verified) on 6 March 2026 - 14:57
Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, imlifidase, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000225594
EMA/PE/0000221462
Submitted by Anonymous (not verified) on 6 March 2026 - 14:56
EMA/PE/0000221462
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000221296
Submitted by Anonymous (not verified) on 6 March 2026 - 14:54
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000221296
Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000221213
Submitted by Anonymous (not verified) on 6 March 2026 - 14:54
Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000221213